Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an exploratory genomic analysis of publicly available data identifying potential molecular subsets of pancreatic NETs, raising questions about prognostic stratification but lacking validation, clinical outcomes, or therapeutic testing.
A Scientific Statement outlining quality standards and best practices for preclinical cardio-oncology research, intended to promote standardization, reproducibility, and rigor in the field.
A retrospective cohort study with adequate sample size and sound methodology demonstrating that myocardial work parameters detect cardiac dysfunction earlier than ejection fraction, but requiring prospective validation and external replication to confirm clinical utility.
A narrative review synthesizing current evidence on circulating biomarkers in cardio-oncology, recommending multimodal assessment strategies but acknowledging gaps in validation and standardization rather than reporting new primary data.
Single-case report demonstrating imaging methodology and concordance patterns in one patient; raises questions about imaging selection and tumor heterogeneity but lacks comparative data, control group, or outcome data to establish clinical utility.
A critical review examining methodological standardization, biological interpretation, and prognostic validation of pathologic response assessment in NSCLC, offering expert recommendations for harmonization and future strategies.
FDA accelerated approval of zidesamtinib for ROS1-positive NSCLC in treatment-experienced patients, based on phase 1/2 trial data showing durable efficacy and manageable safety.